trending Market Intelligence /marketintelligence/en/news-insights/trending/l_NYIPKccxc5n8ZOF4xsxA2 content esgSubNav
In This List

Lupin receives FDA approval to market generic antidepressant drug

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Lupin receives FDA approval to market generic antidepressant drug

India-based Lupin Ltd. received U.S. FDA approval to market its Paroxetin extended release tablets, a generic of Apotex Technologies Inc.'s Paxil CR tablets.

The drug is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.

Lupin will begin promoting the product soon.